Intravenous immunoglobulin for Guillain-Barré syndrome

Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.

The use of intravenous infusions of immunoglobulin in the treatment of Guillain-Barre syndrome has become widespread. However, this treatment is not without morbidity. We describe an acute encephalopathy occurring in a patient receiving intravenous immunoglobulin infusions for Guillain-Barre syndrome. A 55 year old woman was admitted with a four week history of malaise and occasional rigors and...

Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome

A new randomised controlled trial suggested that plasma exchange hastened removal from the ventilator in mechanically ventilated children with Guillain-Barré syndrome compared with intravenous immunoglobulin. Two larger trials in adults showed the opposite result.

Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.

Guillain-Barré syndrome (GBS) is an acute neuropathy and a clinical syndrome that includes a number of pathological and electrophysiological subtypes. Intravenous immunoglobulin (IVIG) and plasma exchange (PE) are both equally efficacious for the treatment of GBS; however, the cost of IVIG may be lower for both the patient and the healthcare system. To compare the pharmacoeconomics of PE and IV...

Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome.

Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain–Barré syndrome

The majority of adverse reactions of intravenous immunoglobulin (IVIG) therapy are mild, transient and self-limiting with potentially serious complications occurring in <5% of patients. IVIG-associated transient aseptic meningitis is one such rare adverse effect, which has been seldomly described in the literature. We report a case of aseptic meningitis due to IVIG therapy in a Guillain-Barré s...